
AmbrisentanQuality Solutions

Category: Cardiovascular



Authorized Distributor

USP can support your development and manufacturing activities on Ambrisentan-based medicines with these existing and upcoming standards.

Official and Proposed Documentary Standards and Associated Physical Materials

MONOGRAPH 1

AMBRISENTAN Published in PF 50(2) 31-May-2024	
USP Ambrisentan RS NEW	<u>USP-1019111</u>
USP Ambrisentan Related Compound A RS NEW	<u>USP-1019122</u>
USP Ambrisentan Related Compound B RS NEW	<u>USP-1019133</u>
USP Ambrisentan Related Compound C RS NEW	<u>USP-1019144</u>
USP Ambrisentan Related Compound D RS NEW	<u>USP-1019155</u>
USP Ambrisentan Related Compound E RS NEW	<u>USP-1019166</u>
USP Ambrisentan R-Enantiomer RS NEW	<u>USP-1019188</u>

INCLUDED GENERAL CHAPTERS

<11> USP REFERENCE STANDARDS

Official as of 01-Nov-2020

<197> SPECTROSCOPIC IDENTIFICATION TESTS

Official as of 01-Sep-2021

<281> RESIDUE ON IGNITION

Official as of 31-Dec-2012

<921> WATER DETERMINATION
Official as of 01 May 2022

Official as of 01-May-2022

USP Sodium Tartrate Dihydrate RS <u>USP-1614909</u>

Disclaimer: USP Quality Solution Sheets are provided as a convenience and for informational purposes only. Labmix24 makes reasonable efforts to provide correct information but assumes no liability for the completeness, timeliness or accuracy of the information contained in each QSS. It is the responsibility of the user to verify the information. The US Pharmacopeia remains the official source of this information.

